Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OVAFIT-TIL in Recurrent Ovarian Cancer
NCT07720180Phase 2Not yet recruiting
- Sponsor
- Medical University of South Carolina
- Start
- Dec 2026
- Primary completion
- Dec 2031
- Countries
- 1
01
Overview
A Phase 2 trial of GC101 TIL + pembrolizumab in ovarian cancer, sponsored by Medical University of South Carolina. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
GC101 TIL + pembrolizumab
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT07720180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07720180.